Muscles need dystrophin in order to regenerate. Persons suffering from Duchenne muscular dystrophy lack this essential muscular protein due to mutations in the gene which is responsible for producing dystrophin. As a result, their existing muscle cells deteriorate over time and are gradually replaced by connective and fatty tissue; muscle strength weakens during the course of the disease. The first symptoms usually appear around the age of five. Children with the disease begin to have difficulties with movements they previously completed with ease, for example climbing stairs or getting up from the floor. At approximately the age of twelve, they are no longer able to walk, later losing movement in their arms and hands. Due to concomitant respiratory and cardiac failure, the majority of patients does not reach the age of 40. DMD affects mainly boys, since the responsible mutations are located in the dystrophin gene on the X chromosome.
Gene scissors remove defective gene sequence
An interdisciplinary Munich research team led by scientists from TUM has for the first time succeeded in correcting the mutated dystrophin gene in living pigs. In order to cut the defective gene sequence from the DNA of the animals’ muscle and heart cells, the researchers modified the Crispr-Cas9 gene scissors. “These gene scissors are highly efficient and specifically corrected the dystrophin gene,” says Prof. Wolfgang Wurst, developmental geneticist at TUM and the German Research Center for Environmental Health. It became then again possible to viably read the gene which had been unreadable because of the genetic defect, thus allowing for a successful protein biosynthesis. Now the shorter but stably formed dystrophin protein was able to improve muscle function. The animals treated were less susceptible to cardiac arrhythmia and had an increased life expectancy compared to animals with the disease that did not receive the therapy.
A permanent therapy
“Muscle and heart cells are long-lived cell structures. One half of all myocardial cells remain functional from birth throughout the entire lifecycle of a human being,” says Prof. Christian Kupatt, cardiologist at university hospital TUM Klinikum rechts der Isar. “The genome of a cell is used for protein biosynthesis as long as the cell is alive, and once a cell has been affected by the therapy, it remains corrected. So if we change the genome of a myocardial cell, the correction is a long-term success, in contrast to the results of previous methods.”
Therapeutic success with clinically relevant model
The gene sequence responsible for the dystrophin protein has already been successfully corrected in the past, however in mice and other animal models. “Our results are very promising, since for the first time, we have now been able to demonstrate therapeutic success in a clinically relevant large animal model,” says Prof. Maggie Walter, neurologist at the LMU university hospital. In terms of important biochemical, clinical and pathological changes, the pig model mirrors Duchenne muscular dystrophy in humans. “Since the disease proceeds faster in our pig model, we were able to verify the efficacy of the therapeutic approaches within a manageable period of time,” says Prof. Eckhard Wolf, LMU specialist in veterinary medicine.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Duchenne muscular dystrophy
- Duchenne Muscular Dystrophy Drugs Market 2021 Share, Size Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2025on January 12, 2021 at 6:38 am
Global Duchenne Muscular Dystrophy Drugs Market Research Report focuses on market size, status and forecast 2020-2025, along with this report also focuses on market opportunities and treats, risk ...
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate ...on January 12, 2021 at 6:24 am
Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to ...
- Sarepta Stock Dropped 50% After Gene-Therapy Setback. What to Do Now.on January 8, 2021 at 9:23 pm
The shares lost about half of their value after the company disclosed disappointing trial results for a gene therapy meant to cure Duchenne muscular dystrophy.
- Sarepta Tanks On Likely 2-Year Delay For Muscular Dystrophy Gene Therapyon January 8, 2021 at 2:30 pm
Sarepta Therapeutics' (SRPT) gene therapy targeting muscular dystrophy could be delayed for two years, an analyst said Friday as SRPT stock ...
- CureDuchenne Congratulates Pfizer on Dosing First Patient in Phase III Clinical Trial for Duchenne Muscular Dystrophyon January 8, 2021 at 9:57 am
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy, celebrates Pfizer Inc’ s announcement surrounding the first dosing of a patient with ...
Go deeper with Google Headlines on:
Duchenne muscular dystrophy
Go deeper with Bing News on:
Gene correction therapy
- Homology Medicines (NASDAQ:FIXX) Rating Lowered to Hold at Zacks Investment Researchon January 14, 2021 at 12:40 am
Homology Medicines (NASDAQ:FIXX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
- Stem Cell Therapy for Cystic Fibrosis: Current Status and Future Prospectson January 9, 2021 at 3:59 pm
In addition, the duration of gene expression has been ... An approach considering stem cell-based therapy of CF-injured lungs should achieve a permanent correction of the CF genetic defect.
- Base Editing Shows Promise for Progeria in Mouse Modelon January 6, 2021 at 2:23 pm
Gene correction in an animal model for premature aging has been reported by investigators from the Broad Institute, Vanderbilt University, and NIH.
- Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conferenceon January 3, 2021 at 10:00 pm
Details for the company presentation are as follows: 39th Annual J.P. Morgan Healthcare Conference Date: Wednesday, January 13, 2021 Time: 2:00 - 2:40 p.m. ET A live webcast of the presentation will ...
- Correction to Treatments for Macular Degeneration Article on June 8 -- Journal Reporton December 23, 2020 at 3:59 pm
In a Phase 1-2 trial of Regenxbio's RGX-314 gene therapy for age-related macular degeneration, levels of an antibody produced by the treatment, which blocks a protein that causes AMD, hadn't ...